File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Efficacy of beta-interferon in relapsing multiple sclerosis among Hong Kong Chinese

TitleEfficacy of beta-interferon in relapsing multiple sclerosis among Hong Kong Chinese
Authors
Issue Date2016
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
The 21st Medical Research Conference, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 16 January 2016. In Hong Kong Medical Journal, 2016, v. 22 suppl. 1, p. 36, abstract no. 54 How to Cite?
AbstractINTRODUCTION: Multiple sclerosis (MS) is the most common central nervous system inflammatory demyelinating disorder characterised by relapsing neuroinflammation affecting different regions of the brain, cord, and optic nerves. Beta-interferon (β-IFN) is a first-line disease-modifying drug for MS. METHODS: We retrospectively studied the response to β-IFN of Chinese MS patients followed up in Queen Mary Hospital (QMH). RESULTS: A total of 92 Chinese MS patients who had been followed up by the Neurology Clinic of QMH with follow-up data available were studied. Their mean age at MS onset was 28.8 (range, 12-56) years, mean disease duration 163.3 (range, 6-468) months, and 71 (77.2%) were female. Of the 92 patients, 49 (53.3%) were treated with β-IFN and 41 (44.6%) received β-IFN for 12 months or longer. These 49 patients were studied in detail. Their median duration of β-IFN therapy was 32 (range, 5-204) months and median time from clinical onset to initiation of β-IFN therapy was 39 (range, 2-348) months. The mean annualised relapse rate (ARR) of the 49 patients decreased significantly from pre-treatment 1.19 to post-treatment 0.37; P=0.001 (median, 0.75 to 0.00). Of the 49 patients, 34 (69.4%) had ARR reduction by 30% or more. The median modified Rio score, a measure of clinical relapse and MRI disease activity, was 0.71 at 12 months of β-IFN therapy. Concerning disability, the mean Expanded Disability Status Scale (EDSS) score before β-IFN and after β-IFN therapy/at latest follow-up were 1.8 and 3.3 respectively (median, 2.0 and 2.5, respectively). Overall, 34 (37%) patients had EDSS score of 6 or more at the latest follow-up. Kaplan-Meier analysis reviewed the median time to EDSS score 6 of these 34 patients was 100 months, and there was no difference in median time to EDSS score 6 between those with and without β-IFN therapy for 12 months or longer (85 months vs 100 months; P=0.937 by log-rank test). CONCLUSION: β-IFN therapy for 12 months or longer is moderately effective for prevention of clinical relapse but may not prevent/slow down disability progression in relapsing MS among Hong Kong Chinese.
Persistent Identifierhttp://hdl.handle.net/10722/227550
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorLeung, STS-
dc.contributor.authorChang, SKR-
dc.contributor.authorPang, SYY-
dc.contributor.authorLee, JCY-
dc.contributor.authorLau, KK-
dc.contributor.authorTeo, KC-
dc.contributor.authorChan, KH-
dc.date.accessioned2016-07-18T09:11:23Z-
dc.date.available2016-07-18T09:11:23Z-
dc.date.issued2016-
dc.identifier.citationThe 21st Medical Research Conference, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 16 January 2016. In Hong Kong Medical Journal, 2016, v. 22 suppl. 1, p. 36, abstract no. 54-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/227550-
dc.description.abstractINTRODUCTION: Multiple sclerosis (MS) is the most common central nervous system inflammatory demyelinating disorder characterised by relapsing neuroinflammation affecting different regions of the brain, cord, and optic nerves. Beta-interferon (β-IFN) is a first-line disease-modifying drug for MS. METHODS: We retrospectively studied the response to β-IFN of Chinese MS patients followed up in Queen Mary Hospital (QMH). RESULTS: A total of 92 Chinese MS patients who had been followed up by the Neurology Clinic of QMH with follow-up data available were studied. Their mean age at MS onset was 28.8 (range, 12-56) years, mean disease duration 163.3 (range, 6-468) months, and 71 (77.2%) were female. Of the 92 patients, 49 (53.3%) were treated with β-IFN and 41 (44.6%) received β-IFN for 12 months or longer. These 49 patients were studied in detail. Their median duration of β-IFN therapy was 32 (range, 5-204) months and median time from clinical onset to initiation of β-IFN therapy was 39 (range, 2-348) months. The mean annualised relapse rate (ARR) of the 49 patients decreased significantly from pre-treatment 1.19 to post-treatment 0.37; P=0.001 (median, 0.75 to 0.00). Of the 49 patients, 34 (69.4%) had ARR reduction by 30% or more. The median modified Rio score, a measure of clinical relapse and MRI disease activity, was 0.71 at 12 months of β-IFN therapy. Concerning disability, the mean Expanded Disability Status Scale (EDSS) score before β-IFN and after β-IFN therapy/at latest follow-up were 1.8 and 3.3 respectively (median, 2.0 and 2.5, respectively). Overall, 34 (37%) patients had EDSS score of 6 or more at the latest follow-up. Kaplan-Meier analysis reviewed the median time to EDSS score 6 of these 34 patients was 100 months, and there was no difference in median time to EDSS score 6 between those with and without β-IFN therapy for 12 months or longer (85 months vs 100 months; P=0.937 by log-rank test). CONCLUSION: β-IFN therapy for 12 months or longer is moderately effective for prevention of clinical relapse but may not prevent/slow down disability progression in relapsing MS among Hong Kong Chinese.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleEfficacy of beta-interferon in relapsing multiple sclerosis among Hong Kong Chinese-
dc.typeConference_Paper-
dc.identifier.emailChang, SKR: skrchang@hku.hk-
dc.identifier.emailPang, SYY: syypang@hku.hk-
dc.identifier.emailLau, KK: gkklau@hku.hk-
dc.identifier.emailChan, KH: koonho@hku.hk-
dc.identifier.authorityLau, KK=rp01499-
dc.identifier.authorityChan, KH=rp00537-
dc.identifier.hkuros258973-
dc.identifier.volume22-
dc.identifier.issuesuppl. 1-
dc.identifier.spage36, abstract no. 54-
dc.identifier.epage36, abstract no. 54-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats